Literature DB >> 35001082

Highlights of mechanisms and treatment of obesity-related hypertension.

Elham Shams1, Vijayvardhan Kamalumpundi1, Joshua Peterson1, Ronaldo Altenburg Gismondi2, Wille Oigman3, Marcelo Lima de Gusmão Correia4.   

Abstract

The prevalence of obesity has increased two to three times from 1975 to 2015. Large-scale epidemiological and longitudinal prospective studies link obesity with hypertension. Research suggests that excessive weight gain, particularly when associated with visceral adiposity, may account for as much as 65% to 75% of the risk of incident hypertension. Also, exercise and bariatric/metabolic surgery significantly lowers blood pressure, whereas weight gain increases blood pressure, thus establishing a firm link between these two factors. The mechanisms underpinning obesity-related hypertension are complex and multifaceted, and include, but are not limited to, renin-angiotensin-aldosterone system/sympathetic nervous system overactivation, overstimulation of adipokines, insulin resistance, immune dysfunction, structural/functional renal, cardiac, and adipocyte changes. Though weight loss is the mainstay of treatment for obesity-related hypertension, it is often not a feasible long-term solution. Therefore, it is recommended that aggressive treatment with multiple antihypertensive medications combined with diet and exercise be used to lower blood pressure and prevent complications. The research regarding the mechanisms and treatment of obesity-related hypertension has moved at a blistering pace over the past ten years. Therefore, the purpose of this expert review is two-fold: to discuss the pathophysiological mechanisms underlying obesity-related hypertension, and to revisit pharmacotherapies that have been shown to be efficacious in patients with obesity-related hypertension.
© 2021. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35001082     DOI: 10.1038/s41371-021-00644-y

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   2.877


  61 in total

Review 1.  The pathophysiology of hypertension in patients with obesity.

Authors:  Vincent G DeMarco; Annayya R Aroor; James R Sowers
Journal:  Nat Rev Endocrinol       Date:  2014-04-15       Impact factor: 43.330

2.  The disease burden associated with overweight and obesity.

Authors:  A Must; J Spadano; E H Coakley; A E Field; G Colditz; W H Dietz
Journal:  JAMA       Date:  1999-10-27       Impact factor: 56.272

3.  Global burden of hypertension: analysis of worldwide data.

Authors:  Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He
Journal:  Lancet       Date:  2005 Jan 15-21       Impact factor: 79.321

Review 4.  New developments in the pathogenesis of obesity-induced hypertension.

Authors:  Vasilios Kotsis; Peter Nilsson; Guido Grassi; Giuseppe Mancia; Josep Redon; Frank Luft; Roland Schmieder; Stefan Engeli; Stella Stabouli; Christina Antza; Denes Pall; Markus Schlaich; Jens Jordan
Journal:  J Hypertens       Date:  2015-08       Impact factor: 4.844

5.  Childhood physical, environmental, and genetic predictors of adult hypertension: the cardiovascular risk in young Finns study.

Authors:  Jonna Juhola; Mervi Oikonen; Costan G Magnussen; Vera Mikkilä; Niina Siitonen; Eero Jokinen; Tomi Laitinen; Peter Würtz; Samuel S Gidding; Leena Taittonen; Ilkka Seppälä; Antti Jula; Mika Kähönen; Nina Hutri-Kähönen; Terho Lehtimäki; Jorma S A Viikari; Markus Juonala; Olli T Raitakari
Journal:  Circulation       Date:  2012-06-20       Impact factor: 29.690

Review 6.  Obesity, kidney dysfunction and hypertension: mechanistic links.

Authors:  John E Hall; Jussara M do Carmo; Alexandre A da Silva; Zhen Wang; Michael E Hall
Journal:  Nat Rev Nephrol       Date:  2019-06       Impact factor: 28.314

7.  Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled.

Authors:  Peter Bramlage; David Pittrow; Hans-Ulrich Wittchen; Wilhelm Kirch; Steffen Boehler; Hendrik Lehnert; Michael Hoefler; Thomas Unger; Arya M Sharma
Journal:  Am J Hypertens       Date:  2004-10       Impact factor: 2.689

8.  Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials.

Authors:  Judith E Neter; Bianca E Stam; Frans J Kok; Diederick E Grobbee; Johanna M Geleijnse
Journal:  Hypertension       Date:  2003-09-15       Impact factor: 10.190

9.  FTO gene variant and risk of hypertension: a meta-analysis of 57,464 hypertensive cases and 41,256 controls.

Authors:  Dan He; Maosun Fu; Song Miao; Kikuko Hotta; Giriraj R Chandak; Bo Xi
Journal:  Metabolism       Date:  2014-02-17       Impact factor: 8.694

Review 10.  Are there genetic paths common to obesity, cardiovascular disease outcomes, and cardiovascular risk factors?

Authors:  Tuomo Rankinen; Mark A Sarzynski; Sujoy Ghosh; Claude Bouchard
Journal:  Circ Res       Date:  2015-02-27       Impact factor: 17.367

View more
  1 in total

1.  Effects of adrenergic-stimulated lipolysis and cytokine production on in vitro mouse adipose tissue-islet interactions.

Authors:  Morgana Barroso Oquendo; Estela Lorza-Gil; David Juarez-Lopez; Robert Wagner; Andreas L Birkenfeld; Susanne Ullrich; Felicia Gerst
Journal:  Sci Rep       Date:  2022-09-22       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.